Innovative highly concentrated Omega-3 Specialized Nutrition Product

Informazioni relative al progetto

LIFEOMEGA

ID dell’accordo di sovvenzione: 755889

DOI 10.3030/755889

Progetto concluso

Data di avvio 1 Marzo 2017

Data di completamento 30 Novembre 2020

Finanziato da

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Bilancio complessivo € 2 478 024,46

Contributo UE € 1 712 046,88

Coordinato da

SOLUTEX GC SL
Spain

Obiettivo

The objective of the project is the industrial and market development of a high concentrated Omega3 EPA nutritional product addressed to improve the health of cancer patients.

LIFEOMEGA-cancer can be considered one chemotherapy essential nutrient co-adjuvant by overcoming:

1. The deficit of necessary level essential Omega3 EPA fatty acid by one efficient concentration and daily dosage (min 2.2 g EPA per day)
2. On a convenient way for the patient overcoming unpleasant fishy taste and with one unique delivery form

The product is protected by IP and constitutes a unique product and solution, not present in the market. Moreover, it is flavourized, and being an emulsion, it can be conveniently delivered in other liquids. These features make the product a complete breakthrough Medical Food in the essential nutrition market, both in Europe and in the USA.

Cancer patients receiving chemotherapy will be highly benefitted with LIFEOMEGA product; they can have their treatments (as cancer chemo/radiotherapy treatments) outcomes improved, their length of hospital stay reduced, and their quality of life during and after treatment increased. The high convenience allows the consumption of fewer dosages to achieve the targeted Omega3 levels.

LIFEOMEGA has a great potential, as it is estimated that cancer patients recieving chemotherapy unfortunately won't be less than 1 millon / year during the next 11 years, in USA, Spain, France, Germany, UK and Italy.

Campo scientifico

• scienze naturali › scienze biologiche › biochimica › biomolecole › lipidi
• scienze mediche e della salute › scienze della salute › nutrizione
• scienze mediche e della salute › medicina clinica › oncologia

Programma(i)

• H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme
• H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy
• H2020-EU.3.2.1. - Sustainable agriculture and forestry
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet

Argomento(i)

• SMEInst-07-2016-2017 - Stimulating the innovation potential of SMEs for sustainable and competitive agriculture, forestry, agri-food and bio-based sectors

Invito a presentare proposte

H2020-SMEInst-2016-2017

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEINST-2-2016-2017

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

SOLUTEX GC SL

• Contribution nette de l'UE: € 1 712 046,88
• Indirizzo: Ctr de barajas 24 3-4 parque empresarial omega edificio gamma ; 28108 Alcobendas madrid ; Spagna
• Regione: Comunidad de Madrid › Comunidad de Madrid Madrid
• Tipo di attività: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Altri finanziamenti: € 765 977,58